52.23 0.00 (0.00%)
After hours: 4:50PM EDT
|Bid||52.19 x 900|
|Ask||52.20 x 1400|
|Day's Range||51.85 - 52.33|
|52 Week Range||41.23 - 52.33|
|Beta (3Y Monthly)||0.86|
|PE Ratio (TTM)||21.21|
|Forward Dividend & Yield||1.27 (2.49%)|
|1y Target Est||49.41|
Feb.01 -- Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk A/S, the world's biggest maker of diabetes drugs, discusses earnings, the company's growth potential, pricing and a proposal by the administration of U.S. President Donald Trump to limit the discounts pharma companies pay middlemen that have been criticized for driving up costs for patients. Jorgensen speaks on "Bloomberg Markets: European Open."
If you are interested in cashing in on Novo Nordisk A/S's (CPH:NOVO B) upcoming dividend of ø5.15 per share, you only have 4 days left to buy the shares beforeRead More...
Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.
PLAINSBORO, N.J., March 1, 2019 /PRNewswire/ -- Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (insulin aspart injection) 100 u/mL, seeking approval for use as a new mealtime insulin for children and adolescents with type 1 diabetes. Fiasp® is currently approved to control high blood sugar in adults with diabetes. Managing diabetes around mealtimes can be hard1, with parents of young children with type 1 diabetes reporting that this was one of the most problematic areas2.
Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
The year got off to a slow start for the pharma sector from the perspective of regulatory decisions, with the partial government shutdown not helping matters. FDA Commissioner Scott Gottlieb clarified ...
A/S is forecasting a rise in the working capital it would need as it prepares for a potentially disruptive Brexit, including product stockpiles and alternative means of drug transportation. The Bagsvaerd, Denmark-based company is currently storing 16 weeks of drug supply in the U.K. ahead of Britain’s exit from the European Union on March 29. This will result in higher working capital at Novo in the coming quarters, said Mr. Knudsen, without quantifying the potential increase.
COPENHAGEN (Reuters) - The chief executive of drugmaker Novo Nordisk on Friday welcomed a proposal calling for an end to the industry practice of offering after-market discounts called rebates to pharmacy ...
On a per-share basis, the Bagsvaerd, Denmark-based company said it had net income of 54 cents. The drugmaker posted revenue of $4.55 billion in the period. For the year, the company reported profit of ...
Novo Nordisk reported solid growth for its new diabetes drug on Friday and said it would submit a tablet version, a key growth hope, for U.S. approval in the first quarter, lifting the Danish drugmaker's shares. The world's top maker of diabetes drugs expects 2019 sales growth of 2-5 percent and operating profit growth of 2-6 percent, both measured in local currency. Novo faces pressure on prices from competitors and lawmakers in the United States and is pinning its growth hopes on a once-weekly injection and tablet version of its GLP-1 drug semaglutide for diabetes, as well as anti-obesity treatments.